AXGN: Axogen Company Sales Revenue

AxoGen, Inc. (AXGN) is setting the standard for neurosurgery by combining physician training with innovative grafts. The company's consolidated sales confirm this growth, with the parameter value reaching 0.27. The business maintains global leadership in nerve regeneration through the Avance platform while simultaneously optimizing donor raw material supply chains to minimize dependence on external laboratories.

Revenue and Sales Volume: Axogen (AXGN) for 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Axogen (AXGN)

- current price and projected stock value:

Share Price Axogen Surgical|AXGN - Consensus Target

- market capitalization information:

Market Value AxoGen, Inc.|AXGN - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share Axogen|AXGN - Book Capitalization|Market-to-Book Ratio axogeninc.com|AXGN - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

AXGN - Net Income|Expected Net Income AxoGen, Inc.|AXGN - P/E Multiple|Projected Price to Earnings Ratio axogeninc.com|AXGN - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple AxoGen, Inc.|AXGN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Axogen|AXGN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months axogeninc.com|AXGN - Earnings per share growth in current year|Net earnings per share change forecast for next year AxoGen, Inc.

- company sales and revenue statistics:

AXGN - Company Revenue|Company Future Sales Volume Axogen Surgical|AXGN - P/S Multiple|Market Cap to Future Revenue Ratio AxoGen, Inc.

Summary company analysis:AXGN Axogen Surgical

Sales reflect the aggregate cash flow from product realization, determining the fundamental value of the business. By analyzing the gross sales volume dynamics of AxoGen, Inc. (AXGN), an investor assesses the pace of the company's commercial expansion. This metric aggregates all proceeds before deducting operating expenses. For this issuer, revenue stability depends directly on the reliability of external biomaterial suppliers. Outsourcing risks related to sterilization may create volatility for this key indicator.

Key competitors